In patients with C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli resulting in C3 deposition and inflammation. By binding to factor B ...

"We look forward to discussing the data with regulators so we can bring this first-in-class alternative complement pathway inhibitor as the first oral monotherapy to people living with PNH," he added.

These tests are intended to evaluate abnormalities in the alternative complement pathway. If the C3NeF assay is positive, plasma exchange or infusion should be considered, as should administration ...

Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway. Patients have been relying on supportive care, broad immunosuppression and symptom management so far for C3G.

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement ... the complexities of the complement pathways and selection of inhibition ...